S&P 500 Futures
(0.14%) 5 162.00 points
Dow Jones Futures
(0.15%) 38 889 points
Nasdaq Futures
(0.10%) 18 018 points
Oil
(0.82%) $78.75
Gas
(0.51%) $2.15
Gold
(0.63%) $2 323.10
Silver
(2.22%) $27.28
Platinum
(0.20%) $967.20
USD/EUR
(0.02%) $0.929
USD/NOK
(-0.16%) $10.86
USD/GBP
(-0.10%) $0.796
USD/RUB
(0.16%) $91.60

Sanntidsoppdatering for Biomarin Pharmaceutical [BMRN]

Børs: NASDAQ Sektor: Healthcare Industri: Biotechnology
BUY
63.27%
return 3.80%
SELL
38.00%
return 9.91%
Sist oppdatert3 mai 2024 @ 22:00

-1.62% $ 82.44

KJøP 6451 min ago

@ $83.11

Utstedt: 1 mai 2024 @ 21:32


Avkastning: -0.80%


Forrige signal: apr 30 - 21:32


Forrige signal: Selg


Avkastning: 2.70 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):
Profile picture for Biomarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...

Stats
Dagens volum 1.63M
Gjennomsnittsvolum 1.58M
Markedsverdi 15.65B
EPS $0 ( 2024-04-24 )
Neste inntjeningsdato ( $0.570 ) 2024-07-29
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 77.77
ATR14 $2.27 (2.76%)
Insider Trading
Date Person Action Amount type
2024-04-12 Bienaime Jean Jacques Buy 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-12 Bienaime Jean Jacques Sell 20 000 Common Stock
2024-04-11 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
2024-04-12 Bienaime Jean Jacques Sell 20 000 Stock Option (Right to Buy Common Stock)
INSIDER POWER
25.83
Last 93 transactions
Buy: 972 265 | Sell: 563 201

Volum Korrelasjon

Lang: -0.79 (moderate negative)
Kort: -0.97 (very strong negative)
Signal:(29) Possible Trading Opportunity Present (swing)

Biomarin Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner
MMAC0.923
RMRM0.916
FREQ0.89
ABST0.889
IMPL0.889
TTOO0.887
SGBX0.887
INFI0.885
SBBP0.884
CFV0.884
10 Mest negative korrelasjoner
APOP-0.956
ICON-0.907
RDUS-0.893
MIND-0.88
TRMD-0.879
WRLD-0.878
SYKE-0.875
BNIXU-0.873
SOUN-0.873
MGTX-0.873

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Biomarin Pharmaceutical Korrelasjon - Valuta/Råvare

The country flag 0.22
( neutral )
The country flag -0.17
( neutral )
The country flag 0.00
( neutral )
The country flag 0.74
( moderate )
The country flag 0.47
( neutral )
The country flag -0.87
( strong negative )

Biomarin Pharmaceutical Økonomi

Annual 2023
Omsetning: $2.42B
Bruttogevinst: $1.84B (76.15 %)
EPS: $0.890
FY 2023
Omsetning: $2.42B
Bruttogevinst: $1.84B (76.15 %)
EPS: $0.890
FY 2022
Omsetning: $2.10B
Bruttogevinst: $1.61B (76.92 %)
EPS: $0.760
FY 2021
Omsetning: $1.85B
Bruttogevinst: $1.38B (74.52 %)
EPS: $-0.354

Financial Reports:

No articles found.

Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.